Handelsavisen
prelaunch
Companies ›Healthcare ›2629.HK
26
2629.HK — HKEX Biotechnology & Medical Research

Mirxes Holding Company Ltd

HK$12,41
Open in Charts → Attach watcher ⌖
— —
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Mirqes Holding Company Ltd is a biotechnology firm focused on healthcare diagnostics, developing and commercializing molecular diagnostic products for infectious diseases and cancer.

Business. Mirxes Holding Company Ltd (2629.HK) is a biotechnology and medical research company engaged in healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, generating revenue through product sales. Specific operating segments and geographic breakdowns are not disclosed in the available data. The company is primarily listed on the Hong Kong Stock Exchange.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target—

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
—
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
1 analysts · indicative
Ownership
—
not yet wired
Profitability
—
not yet wired
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 2629.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 2629.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Mirxes Holding Company Ltd (2629.HK) is a biotechnology and medical research company engaged in healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, generating revenue through product sales. Specific operating segments and geographic breakdowns are not disclosed in the available data. The company is primarily listed on the Hong Kong Stock Exchange.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    Mirqes operates with a fully diluted share count of 298.23 million shares, matching its basic share count, indicating no dilution from stock options or convertible instruments. The company has not provided balance-sheet data, and no liquidity risk is flagged in source documents, though this precludes a formal liquidity assessment.

    Profitability metrics are not available in the valuation snapshot, and no industry-specific preferred metrics are provided for comparison. Analysts expect a negative EPS of -0.26 USD for the current period, with a mean revenue estimate of 26.54 million USD.

    The company's revenue concentration by segment or geography is not disclosed in available data. No segmental breakdown is provided in the input, and no geographic exposure is quantified.

    Outlook data is limited to analyst estimates, with one "Buy" recommendation and no "Strong Buy" or "Strong Sell" ratings. No numeric revenue or margin growth rates are provided in the input data.

    The company's risk assessment flags liquidity risk as unassessable due to missing balance-sheet inputs and no going-concern language in source documents. Dilution risk is rated as low, with no near-term dilution signals identified in the input.

    No recent filings, transcripts, or material events are disclosed in the input data. The company's financial and operational narrative is limited to analyst estimates and basic share data.

    Key takeaways
    • Mirxes operates in the healthcare diagnostics segment with a focus on molecular testing for infectious diseases and cancer.
    • The company has no near-term dilution risk, with fully diluted shares matching basic shares.
    • Analysts project a negative EPS of -0.26 USD and revenue of 26.54 million USD for the current period.
    • No liquidity risk is flagged, but the absence of balance-sheet data limits formal assessment.
    • Revenue concentration and geographic exposure are not disclosed in available data.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation FY

    Market price
    HK$12,41
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    —
    Net cashⓘ
    —
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    —
    ROEⓘ
    —
    Cash conversionⓘ
    —
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    Operating income · consensus-71,0M USD

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Mirxes Holding Company Ltd Market data — financials · 2026-05-26
    • Mirxes Holding Company Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Leadership

    • Lihan ZhouChief Executive Officer, Executive Director

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    2629.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage